Type II Alexander disease caused by splicing errors and aberrant overexpression of an uncharacterized GFAP isoform. Issue 6 (11th March 2020)

• Record Type: Journal Article
• Authors: Helman, Guy; Takanohashi, Asako; Hagemann, Tracy L.; Perng, Ming D.; Walkiewicz, Marzena; Woidill, Sarah; Sase, Sunetra; Cross, Zachary; Du, Yangzhu; Zhao, Ling; Waldman, Amy; Haake, Bret C.; Fatemi, Ali; Brenner, Michael; Sherbini, Omar; Messing, Albee; Vanderver, Adeline; Simons, Cas
• Is Part Of: Human mutation. Volume 41:Issue 6(2020)
• Page Start: 1131
• Page End: 1137
• Publication Date: 2020-03-11
• Subjects: aberrant splicing -- Alexander disease -- leukodystrophy; Human chromosome abnormalities -- Periodicals; Mutation (Biology) -- Periodicals; 616.04205
• DOI: 10.1002/humu.24008
• Languages: English
• ISSNs: 1059-7794

Abstract

Abstract: Alexander disease results from gain‐of‐function mutations in the gene encoding glial fibrillary acidic protein (GFAP). At least eight GFAP isoforms have been described, however, the predominant alpha isoform accounts for ∼90% of GFAP protein. We describe exonic variants identified in three unrelated families with Type II Alexander disease that alter the splicing of GFAP pre‐messenger RNA (mRNA) and result in the upregulation of a previously uncharacterized GFAP lambda isoform (NM_001363846.1). Affected members of Family 1 and Family 2 shared the same missense variant, NM_001363846.1:c.1289G>A;p.(Arg430His) while in Family 3 we identified a synonymous variant in the adjacent nucleotide, NM_001363846.1:c.1290C>A;p.(Arg430Arg). Using RNA and protein analysis of brain autopsy samples, and a mini‐gene splicing reporter assay, we demonstrate both variants result in the upregulation of the lambda isoform. Our approach demonstrates the importance of characterizing the effect of GFAP variants on mRNA splicing to inform future pathophysiologic and therapeutic study for Alexander disease. Abstract : Variants in the gene encoding glial fibrillary acidic protein (GFAP) cause Alexander disease. At least eight GFAP isoforms have been described, however, the predominant alpha isoform accounts for ∼90% of GFAP protein. Using RNA and protein analysis of brain autopsy samples, and a mini‐gene splicing reporter assay, we demonstrate that some GFAP variants result in the upregulation of uncharacterized GFAP isoforms. Our approach demonstrates the importance of characterizing the effect of GFAP variants on messenger RNA splicing to inform future pathophysiologic and therapeutic study for Alexander disease.